PlainPharmaWatch

CMS Open Payments · Program Year 2024

Pacira Pharmaceuticals Incorporated

Pacira Pharmaceuticals Incorporated reported $5,371,375.94 in payments to 18,305 physicians and teaching hospitals across 18,450 transactions.

See the rankings → How this is sourced
$5.4M
Total payments
18,450
Transactions
18,305
Recipients
−$808.4K
General Payments vs PY2023

Pacira Pharmaceuticals Incorporated reported $5,371,375.94 in payments to 18,305 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #262 of 1,925 reporting manufacturers (0.0% of all US industry payments), averaging $293.44 per recipient across 9 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Pacira Pharmaceuticals Incorporated pairs top-quartile payment volume with an unusually diversified payment pattern across a wide recipient base.

#262
of 1,925 companies
0.0%
of all US industry payments
0.1%
paid to its single top recipient
9
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Pacira Pharmaceuticals Incorporated's CMS-reported General Payments decreased by $808.4K (−14.4%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: PACIRA PHARMACEUTICALS INCORPORATEDPY2023: PACIRA PHARMACEUTICALS INCORPORATEDPY2024: Pacira Pharmaceuticals Incorporated. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$5.6MPY2024$4.8M
PY2023
$5,600,440.44
PY2024
$4,792,036.39

How Pacira Pharmaceuticals Incorporated ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Pacira Pharmaceuticals Incorporated's total vs. every reporting company

CMS Open Payments, Program Year 2024

$5,371,376 Top 14% higher than 86% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). This entry sits in this band. $7,261,783–$22,556,757: 133 reporting companies (7%). Above this entry. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Pacira Pharmaceuticals Incorporated

In Program Year 2024, Pacira Pharmaceuticals Incorporated reported $5,371,375.94 in payments to 18,305 physicians and teaching hospitals across 18,450 individual transactions, an average of $291.13 per transaction and $293.44 per recipient. That total places Pacira Pharmaceuticals Incorporated at rank #262 out of 1,925 companies in the CMS Open Payments database, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

"Consulting Fee" leads the 9-category general-payment breakdown below at $2.3M (42.9% of the company's reported total, 638 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

"Consulting Fee" leads Pacira Pharmaceuticals Incorporated's 9-category general-payment breakdown at $2.3M, 42.9% of the reported total.

How Pacira Pharmaceuticals Incorporated divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$2.3M2. Honoraria$795.8K3. Travel and Lodging$653.5K4. Food and Beverage$539.2K5. Compensation for Faculty …$383.9K6. Space Rental or Facility …$43.4K7. Education$30.0K8. Grant$25.3K9. Long-Term Medical Supply …$19.3K
Payment Type Amount Transactions
Consulting Fee $2.3M 638
Honoraria $795.8K 234
Travel and Lodging $653.5K 2,613
Food and Beverage $539.2K 14,780
Compensation for Faculty or Speaker (Medical Education) $383.9K 7
Space Rental or Facility Fees $43.4K 12
Education $30.0K 1
Grant $25.3K 6
Long-Term Medical Supply or Device Loan $19.3K 14

Recipient Concentration in General Payments

The five largest recipient relationships account for $995,699.28 (20.8%) of $4,792,036.39 in this company's General Payments records across 10,697 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Pacira Pharmaceuticals Incorporated

The five named recipients with the highest reported General Payments from this company

Mark Kronenfeld$277.9KChristopher Paul Varacallo$197.2KMark Froimson$189.6KJeffrey Gadsden$169.1KKarina Gritsenko$161.9K
  1. 1

    Mark Kronenfeld

    $277,850.44 across 20 reported transactions

  2. 2

    Christopher Paul Varacallo

    $197,247.60 across 134 reported transactions

  3. 3

    Mark Froimson

    $189,594.61 across 19 reported transactions

  4. 4

    Jeffrey Gadsden

    $169,085.53 across 134 reported transactions

  5. 5

    Karina Gritsenko

    $161,921.10 across 186 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $291.13. Average per recipient: $293.44.

Total Amount

$5,371,375.94

Avg per Transaction

$291.13

Avg per Recipient

$293.44

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Pacira Pharmaceuticals Incorporated Share

0.0%

#262 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Pacira Pharmaceuticals Incorporated

Valencia Technologies Corporation

$5.4M 473 recipients

KLS-Martin L.P.

$5.3M 6,287 recipients

SpringWorks Therapeutics, Inc.

$5.3M 4,420 recipients

Olympus Corporation of the Americas

$5.2M 4,448 recipients

Mitsubishi Tanabe Pharma America, Inc.

$5.2M 3,683 recipients

BioXcel Therapeutics, Inc.

$5.2M 532 recipients

Frequently Asked Questions

How much did Pacira Pharmaceuticals Incorporated pay to physicians and hospitals in 2024? ▾
0.0% of all industry payments reported to CMS Open Payments for 2024 came from Pacira Pharmaceuticals Incorporated, totaling $5,371,375.94 across 18,450 transactions to physicians and hospitals.
How many physicians received payments from Pacira Pharmaceuticals Incorporated? ▾
Averaging $293.44 per recipient, Pacira Pharmaceuticals Incorporated's 2024 payments reached 18,305 physicians and teaching hospitals.
What types of payments did Pacira Pharmaceuticals Incorporated make? ▾
Pacira Pharmaceuticals Incorporated made 9 different types of general payments (consulting, meals, travel, and similar categories). The largest general-payment category was "Consulting Fee" at $2.3M, representing 42.9% of the company's reported total.
How does Pacira Pharmaceuticals Incorporated rank among pharmaceutical companies? ▾
By total payment amount, Pacira Pharmaceuticals Incorporated sits at #262 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Pacira Pharmaceuticals Incorporated? ▾
The average transaction from Pacira Pharmaceuticals Incorporated was $291.13 in 2024. The company made 18,450 total transactions to 18,305 recipients.
Where does the payment data for Pacira Pharmaceuticals Incorporated come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Pacira Pharmaceuticals Incorporated's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.